7‐day versus 14‐day tegoprazan‐based triple therapy to treat <scp>Helicobacter pylori</scp> infection: Real‐world evidence

Jung, Yoon Suk; Kim, Sunyong; Kim, Sujeong; Noh, Seung Jae; Park, Jung Ho; Park, Chan Hyuk

doi:10.1111/jgh.15939

Cited by 12 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[27][28][29][30] Likewise, previous studies investigating tegoprazan-based TT regimens have shown most AEs to be mild, requiring no medical management, with the most frequent ones being gastrointestinal disorders. [31][32][33][34] Our study found a 23.4% rate of AEs associated with tegoprazan-based TT, consistent with prior studies. Owing to the lack of relevant medical records, AE rates for lansoprazole-based TT could not be determined.…”

Section: Discussionsupporting

confidence: 89%

Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Helicobacter pylori Eradication

Kang,

Kim,

Jeong

et al. 2024

Korean J Helicobacter Up Gastrointest Res

View full text Add to dashboard Cite

Objectives: Tegoprazan, a novel potassium-competitive acid blocker with rapid and effective antisecretory activity, was approved for the treatment of Helicobacter pylori infections in Korea in March 2020. However, real-world data regarding tegoprazan-based therapies are scarce. We compared the efficacies of tegoprazan- and lansoprazole-based triple therapies (TTs).Methods: Between March 2020 and February 2023, this study enrolled patients diagnosed with H. pylori infections who were prescribed either 14-day tegoprazan- or lansoprazole-based TTs as first-line treatments. Their medical records were retrospectively reviewed to compare H. pylori eradication rates and the rates of patient adherence to the recommended therapy.Results: A total of 670 patients diagnosed with H. pylori infections were prescribed 14-day TT regimens between March 2020 and February 2023 at Ilsan Paik Hospital (Goyang, Korea). Of those enrolled in the study, 64 received tegoprazan-based TT and 295 received lansoprazole-based TT as their first-line treatment. The H. pylori eradication rates for tegoprazan- and lansoprazole-based TTs were 76.6% and 75.6%, respectively, in the intent-to-treat population; the rates were 88.9% and 88.4%, respectively, in the per-protocol population (non-inferiority test, p=0.03 and p=0.01 in the respective populations). No significant differences were observed between the two groups with regards to treatment adherence rates (84.4% vs. 85.1%, p=0.78).Conclusions: As a first-line treatment for H. pylori eradication, 14-day tegoprazan-based TT demonstrated non-inferior efficacy compared with 14-day lansoprazole-based TT.

show abstract

Section: Discussionsupporting

confidence: 89%

Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Helicobacter pylori Eradication

Kang,

Kim,

Jeong

et al. 2024

Korean J Helicobacter Up Gastrointest Res

View full text Add to dashboard Cite

show abstract

“…Drug adherence was defined as the administration of ≥80% of prescribed medications. The severity of adverse events was assessed as mild (transient symptoms that improved spontaneously), moderate (symptoms that required management), or severe (symptoms that led to emergency visits) ( 17 ).…”

Section: Methodsmentioning

confidence: 99%

Comparative efficacy of tegoprazan versus esomeprazole/sodium bicarbonate for the treatment of Helicobacter pylori infection

Park

Jung

2023

Clin Transl Gastroenterol

Self Cite

View full text Add to dashboard Cite

Introduction: Potassium-competitive acid blockers and proton pump inhibitors/sodium bicarbonate can rapidly increase intragastric pH. Herein, we aimed to compare the clinical outcomes of tegoprazan-based and esomeprazole/sodium bicarbonate-based triple therapies in the treatment of H. pylori infection. Methods: We retrospectively reviewed the data of patients with H. pylori infection treated with a 14-day tegoprazan-based triple therapy or 14-day esomeprazole/sodium bicarbonate-based triple therapy. The primary endpoint was the H. pylori eradication rate with first-line treatment in an intention-to-treat (ITT) analysis. Secondary endpoints included the eradication rate with first-line therapy in the per-protocol (PP) analysis and adverse events associated with eradication therapy. Results: Of the 854 included patients, 435 were treated with tegoprazan-based therapy and 419 received esomeprazole/sodium bicarbonate-based therapy. In the ITT population, no significant difference in eradication rate was detected between the tegoprazan- and esomeprazole/sodium bicarbonate-treated groups (78.6% [95% confidence interval (CI), 74.6–82.3%] vs. 81.4% [95% CI, 77.4–84.9%], P = 0.313). The PP analysis also revealed a similar eradication rate between groups (tegoprazan vs. esomeprazole/sodium bicarbonate: 85.5% [95% CI, 81.8–87.5%] vs. 87.8% [95% CI, 84.1–90.7%], P = 0.339). However, abdominal discomfort and diarrhea were more common in the esomeprazole/sodium bicarbonate group than in the tegoprazan group (abdominal discomfort: 1.1% vs. 3.8%, P = 0.012; diarrhea: 9.9% vs. 21.2%, P < 0.001). Discussion: The efficacy of the esomeprazole/sodium bicarbonate-based triple therapy for H. pylori eradication was comparable with that of the tegoprazan-based triple therapy. However, esomeprazole/sodium bicarbonate-based therapy exhibited a higher risk for abdominal discomfort and diarrhea than tegoprazan-based therapy.

show abstract

“…Southern Italy is a geographical region where the clarithromycin resistance rate exceeds 20% [6]. For this reason, triple therapy effectiveness has decreased and, therefore, cannot be recommended any more [7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial

Losurdo,

Borraccino,

Aloisio

et al. 2024

Antibiotics

View full text Add to dashboard Cite

Concomitant therapy (CT) and bismuth quadruple therapy (BQT) are recommended in geographical areas with high clarithromycin resistance for Helicobacter pylori (H. pylori) eradication. We compared CT and BQT as the first lines of treatment in a randomized controlled trial. Consecutive patients with H. pylori diagnosed by concordance of both a urea breath test and histology were recruited. For BQT, patients received 3 PyleraTM capsules q.i.d.; for CT, 1000 mg of amoxicillin b.i.d, 500 mg of clarithromycin b.i.d and 500 mg of metronidazole b.i.d. As a proton pump inhibitor, 40 mg of pantoprazole b.i.d was administered. Both regimens lasted 10 days. In total, 46 patients received CT and 38 BQT. Both groups were comparable for age (p = 0.27) and sex (p = 0.36). We did not record any drop outs; therefore, the intention to treat and per protocol rates coincided. The most common symptoms were heartburn and post-prandial fullness, which were equally present in both groups. The success rate was 95.6% for CT and 100% for BQT (p = 0.56). Side effects were recorded in 23.9% and 31.6% of patients in the CT and BQT arms, respectively (p = 0.47). The most common ones were abdominal pain (8) and diarrhea (6). In conclusion, CT and BQT are equally effective in our area with high clarithromycin resistance, southern Italy, and showed comparable safety.

show abstract

7‐day versus 14‐day tegoprazan‐based triple therapy to treat Helicobacter pylori infection: Real‐world evidence

Cited by 12 publications

References 22 publications

Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Helicobacter pylori Eradication

Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Helicobacter pylori Eradication

Comparative efficacy of tegoprazan versus esomeprazole/sodium bicarbonate for the treatment of Helicobacter pylori infection

Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial

Contact Info

Product

Resources

About